Announcements Trials

Browse Landscape

Phase

Phase 1 3 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 32 Multiple Endocrine Neoplasia Type 1 9 Neoplasms 8 Pituitary Neoplasms 7 Carcinoid Tumor 7 Pituitary ACTH Hypersecretion 6 Gastro-enteropancreatic neuroendocrine tumor 6 Differentiated Thyroid Cancer 6 Adrenocortical Carcinoma 6 Thyroid Cancer, Papillary 5 Pituitary Diseases 5 Pheochromocytoma 5 Thyroid Neoplasms 4 Serotonin Syndrome 4 Neuroblastoma 4 Cushing Syndrome 4 Breast Neoplasms 4 Acromegaly 4 ACTH Syndrome, Ectopic 4 Sarcoma 3 Liposarcoma 3 Insulinoma 3 Fibrosarcoma 3 Endometrial Neoplasms 3 Carcinoma, Medullary 3 Adenoma, Islet Cell 3 Adenocarcinoma, Follicular 3 Sarcoma, Synovial 2 Sarcoma, Endometrial Stromal 2 Parkinson Disease 2

Interventions

Everolimus 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Thymus Neoplasms × Endocrine × Clear all

NCT05918302 2026-05-12

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡